**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 32752**

**Manuscript Type: EVIDENCE-BASED MEDICINE**

**Antimicrobial susceptibility testing before first-line treatment for *Helicobacter pylori* infection in patients with dual or triple antibiotic resistance**

Cosme A *et al.* Treatment of *H. pylori* with dual or triple resistance

Angel Cosme, Milagrosa Montes, Begoña Ibarra, Esther Tamayo, Horacio Alonso, Usua Mendarte, Jacobo Lizasoan, Marta Herreros-Villanueva, Luis Bujanda

**Angel Cosme,** **Begoña Ibarra, Horacio Alonso, Usua Mendarte, Jacobo Lizasoan, Marta Herreros-Villanueva, Luis Bujanda,** Gastroenterology Department, Donostia Hospital-Biodonostia Health Research Institute, University of Basque Country, Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas, 20010 San Sebastián, Spain

**Milagrosa Montes,Esther Tamayo,** Microbiology Department, Hospital Universitario Donostia-Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, 20010 San Sebastián, Spain

**Milagrosa Montes**, Epidemiology Department, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Donostia Hospital, 20010 San Sebastián, Spain

**Marta Herreros-Villanueva,**Faculty of Life Science, Universidad Isabel I, 09003 Burgos, Spain

**Author contributions:** Cosme A and Bujanda L designed the study; Montes M, Ibarra B, Tamayo E, AlonsoH, MendarteU, LizasoanJ, Cosme A, Bujanda L and Herreros-Villanueva M coordinated and participated the clinical study; Cosme A, Bujanda L and Herreros-VillanuevaM wrote and edited the manuscript.

**Conflict-of-interest statement:** Attached in a sepatate file as 3 32752 Copyright assignment

**Data sharing statement:** All study participants, or their legal guardian, provided informed written consent. All the data from participants are here anonymized and there is not risk of identification.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Dr. Luis Bujanda,** Gastroenterology Department, Donostia Hospital-Biodonostia Health Research Institute, University of Basque Country (UPV/EHU), Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Avda Sancho El Sabio 17-2ºDcha, 20010 San Sebastián, Spain. medik@telefonica.net

**Telephone**: +34-943-007173

**Fax**: +34-943-007065

**Received:** January 21, 2017

**Peer-review started:** January 22, 2017

**First decision:** February 10, 2017

**Revised:** February 19, 2017

**Accepted:** March 15, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To evaluate the efficacy of antimicrobial susceptibility-guided therapy before first-line treatment for infection in patients with dual or triple antibiotic resistance.

***METHODS***

A total of 1034 patients infected by *Helicobacter pylori* (*H. pylori*) during 2013-2014 were tested for antimicrobial susceptibility. 157 of 1034 (15%) patients showed resistance to two (127/1034; 12%) and to three (30/1034; 3%) antibiotics. Sixty-eight patients with dual HP-resistance (clarithromycin, metronidazole or levofloxacin) were treated for 10 days with triple therapies: OAL (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and levofloxacin 500 mg b.i.d.) 43 cases, OAM (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and metronidazole 500 mg b.i.d.) 12 cases and OAC (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and clarithromicin 500 mg b.i.d.) 13 cases based on the antimicrobial susceptibility testing. Twelve patients showed triple HP-resistance (clarithromycin, metronidazole and levofloxacin) and received for 10 d triple therapy with OAR (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and rifabutin 150 mg b.i.d.). Eradication was confirmed by 13C-urea breath test. Adverse effects and compliance were assessed by a questionnaire.

***RESULTS***

Intention-to-treat eradication rates were: OAL (97.6%), OAM (91.6%), OAC (92.3%) and OAR (58.3%). Cure rate was significantly higher in naïve patients treated with OAR-10 compared to patients who had two or three previous treatment failures (83% *vs* 33%). Adverse events rates for OAL, OAM, OAC and OAR were 22%, 25%, 23% and 17%, respectively, all of them mild-moderate.

***CONCLUSION***

Antimicrobial susceptibility-guided triple therapies during 10 d for first-line treatment leads to an eradication rate superior to 90% in patients with dual antibiotic *H. pylori* resistance

**Key words:** *Helicobacter pylori*; Resistance; Eradication rate; Antimicrobial susceptibility; Therapies

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study evaluated the efficacy of antimicrobial susceptibility-guided therapy: proton-pump inhibitor and two or three antibiotics for ten days before first-line treatment in patients with dual or triple Helicobacter pylori resistance to clarithromycin, metronidazole and/or levofloxacin. Intention to treat analysis demonstrates that eradication rates in patients with dual *Helicobacter pylori* resistance are high (around 95%). Cure rate was significantly higher in naive patients with dual resistance compared to those with triple resistance (95% *vs* 83%).

Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for *Helicobacter pylori* infection in patients with dual or triple antibiotic resistance. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

*Helicobacter pylori* (HP) eradication therapy success is compromised mainly due to antibiotic resistance. Resistance prevalence varies by country and within same region by periods of time. Among possible causes of failure are the increased use of different antibiotics in the general population- adult and children for dental, respiratory, gynecological and parasitic infectious diseases.

Prevalence of HP antibiotic resistance has been increasing remarkably worldwide and concordantly, eradication rate has been declining globally[1]. Since multiresistance is frequently developed against most commonly implemented antibiotics and this phenomena leads to an increasing inadequate success rates, new therapeutic strategies are urgently needed.

In Gipuzkoa, a region in Northern Spain, during 2006-2012 the prevalence of clarithromycin-resistant HP varied from 15.7% to 21.6% and from 32% to 44.3% for metronidazole. Between 2000 and 2012, the resistance to two or three antibiotics (clarithromycin, metronidazole, or/and levofloxacin) was observed in 14.8% of 5998 HP isolates tested for antimicrobial susceptibility[2].

The objective of our study was to evaluate the efficacy of antimicrobial susceptibility-guided therapy: proton-pump inhibitor (PPI) and two antibiotics for ten days before first-line treatment in patients with dual HP-resistance (clarithromycin, metronidazole or levofloxacin) or triple HP-resistance (clarithromycin, metronidazole and levofloxacin).

**MATERIALS AND METHODS**

***Patients and study protocol***

This was a prospective observational study including all patients infected by HP during 2013 and 2014 in our region. Susceptibility testing was performed in all strains isolates from gastric biopsies. Exclusion criteria included severe concomitant disease (insulin-dependent type I diabetes mellitus and neoplastic diseases), previous gastric surgery, pregnancy or lactation, and allergy to any of the drugs used in the study.

This study was conducted in accordance with the principles of the Declaration of Helsinki, ICH Guidelines for Good Clinical Practice and full conformity with relevant regulations.

***Culture and microbial susceptibility testing***

For each patient, two antral and two corpus biopsies were taken for the bacterial culture. Susceptibility testing was assessed by E-test (BioMerieux) in 1034 patients. Primary and relapse isolates were included. E-test strips were placed on *Brucella* agar plates with 5% hemolized horse blood, supplemented with 1% Vitox and were incubated at 37 ºC for 48-72 h under microaerophilic conditions with 80% humidity[3].

It was observed that 53.3% (551/1034) of isolates were resistant to at least one antibiotic, 12.3% of them to two antibiotics and 2.9% to three antibiotics (Figure 1). In Gipuzkoa the rate of HP amoxicillin resistance was 0%. It is well known that resistance to clarithromycin and fluoroquinolone are mainly codified in the 235rsRNA and gyrA genes, respectively.

***Therapeutic regimen***

Patients with dual HP-resistance were treated based on the antimicrobial susceptibility results: (1) levofloxacin-based triple therapy: omeprazole 20 mg, amoxicillin 1 g, and levofloxacin 500 mg (OAL), if the HP-isolates were resistant to clarithromycin and metronidazole but sensitive to levofloxacin; (2) metronidazole-based triple therapy: omeprazole 20 mg, amoxicillin 1 g, and metronidazole 500 mg (OAM), if the HP-isolates were resistant to both clarithromycin and levofloxacin but sensitive to metronidazole; and (3) clarithromycin-based triple therapy: omeprazole 20 mg amoxicillin 1 g, and clarithromycin 500 mg (OAC), if the HP-isolates were resistant to metronidazole and levofloxacin but sensitive to clarithromycin, in all cases twice a day for 10 d.

Patients with triple HP-resistance to clarithromycin, metronidazole and levofloxacin received rifabutin-based triple therapy: omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and rifabutin 150 mg b.i.d. (OAR) for 10 d. No patients had previously received rifampicin and 6 of them referred two or three HP eradication failures (3 with OAC and bismuth quadruple therapy, 2 with OAC, bismuth quadruple therapy and OAL, and 1 with OAC and OAL, in all cases for 10 d).

Treatment was clearly explained to all patients. Drugs were self-administered orally after meals. Drugs used in all groups were generic branding.

***Trial outcomes***

Primary end point: confirmed HP eradication by intention-to-treat (ITT) in each group of at least 6 wk after treatment completion using the urea breath test (UBT) with 100 mg of urea, in accordance with a previously described protocol[3].

Secondary end point: adherence to treatment regimen and adverse events associated with treatment. Adherence to treatment was defined as in take of –at least- 90% of the medication prescribed assessed by using a questionnaire and counting empty medication sachets returned. Side effects were evaluated with a specific postreatment questionnaire completed. Depending of the intensity, adverse effects were classified by physicians as mild (symptoms appear but do not interfere with daily life), moderate (symptoms interfere with daily life) or severe (symptoms prevent daily life or requires discontinuation of the drug).

**RESULTS**

A total of 1034 HP-positive consecutive adult patients with antimicrobial-susceptibility testing were enrolled from January 2013 to December 2014 in Gipuzkoa (Basque Country), a region in Northern Spain of around 700000 residents. Considering the total of patients, dual HP-resistance to two antimicrobials (clarithromycin, metronidazole or levofloxacin) was observed in 127 (12.3%) and triple HP-resistance to three antimicrobials in 30 (2.9%) of them. Patients with dual HP-resistance were treated with OAL-10, OAM-10 or OAC-10 d, and patients with triple HP-resistance with OAR-10 d. A subgroup of 80 patients (68 with dual HP-resistance, and 12 with triple HP-resistance) attending to Donostia Hospital (San Sebastián, Spain) were only included. The population represented in this area of San Sebastián is around 393000 residents (Figure 2).

Baseline characteristics of each group of patients, efficacy of therapy on HP-eradication, compliance and adverse events are shown in Table 1. ITT analysis demonstrated that eradication rates in patients with dual HP-resistance treated with OAL-10, OAM-10, and OAC-10 were 97.6% (42/43), 91.6% (11/12) and 92.3% (12/13), respectively, and with triple HP-resistance treated with OAR-10, 58.3% (7/12). The eradication rate in naïve patients with OAR-10 was 83% (5/6) and 33% (2/6) in patients after previous regimen failures (OAC and bismuth quadruple therapy, and OAC, bismuth quadruple therapy and OAL, respectively).

Seventy-five out of 80 patients with dual or triple HP-resistance showed 100% compliance to prescribed medications. No significant differences were observed in compliance between patients with dual and triple HP-resistance (93% *vs* 94% respectively).

Adverse events rate for OAL, OAM, OAC, and OAR were 22% (abdominal pain in 3 patients, nausea in 3 patients, asthenia in 1 patient, diarrhea in 1 patient and metallic taste in 1 patient), 25% (myalgia in 1 patient and metallic taste in 2 patients), 23% (diarrhea in 1 patient, nausea in 1 patient and metallic taste in 1 patient) and 11% (headache in 1 patient, and increased transaminases in 1 patient) respectively, all of them classified as mild to moderate.

**DISCUSSION**

In this study we demonstrated that in patients with dual clarithromycin, levofloxacin or metronidazole resistance, antimicrobial susceptibility-guided therapy including a combination of PPI and two antibiotics for 10 d leads to an eradication rate (evaluated by ITT) of 95.5%.

In our reference center-Donostia Hospital, cultures are carried out as “routine practice” since 1994[4]. During 1994-1998 dual HP-resistance to two antimicrobials (clarithromycin, metronidazole or levofloxacin) was 10.5%[4,5]. In Gipuzkoa (Basque country), from 2000-2012 the dual resistance was observed in 12.4% of isolates of HP[2], being 12.3% considering the period 2013-2014. By contrast, multiple HP-resistance to three antimicrobials increased from 2.4% during the period 2000-2012 to 2.9% for the period 2013-2014.

Patients with dual or triple resistance represents a new scenario to evaluate efficacy of current antibiotics regimens. According to the Maastrich V/Florence Consensus Conference on managing HP, bismuth quadruple therapy (BQT) for first-line treatment or non-bismuth quadruple concomitant therapy (non-BQT) as alternative were recommended when clarithromycin resistance of HP is > 15%, metronidazole HP-resistance is less than 40% and dual clarithromycin and metronidazole HP-resistance is < 15%[6].

In patients with dual clarithromycin and metronidazole HP resistance, Georgopoulos *et al*[7], reported 78% (18 out 23) of eradication rates when non-bismuth quadruple concomitant therapy (PPI regime plus amoxicillin, clarithromycin and metronidazole for 10 d) was prescribed and 33% (9 out 27) with quadruple sequential therapy administration (5 days PPI plus amoxicillin, followed by a further 5 d with clarithromycin and metronidazole). Recently, in the European *H. pylory* Registry (31 countries and 18270 pacients with complete treatment, 12% of them with culture and antibiogram), eradication rates with quadruple concomitant and sequential therapy were 80% (4 of 5) and 62.5% (5 of 8) respectively[8].

On the other hand, the eradication rate with bismuth quadruple therapy for 10 days was lower in pretreated patients with metronidazole resistance[9,10]. Furthermore, different studies analyzing bismuth quadruple therapy concluded that *in vitro* resistant strains to metronidazole could be effectively heated by using higher doses of metronidazole administrated for 14 d[11, 12]. However, this classic bismuth quadruple therapy requires a complex scheme of administration, increases size effects and it is not worldwide available due to distribution restrictions.

A number of strategies have been recommended to potentially overcome dual HP-resistance (clarithromycin and metronidazole) including longer duration of quadruple therapies (concomitant-14 d, bismuth -14 d), higher dose of new-generations – PPIs (esomeprazole or rabeprazole), hybrid therapy (a 7 d of PPI plus amoxicillin, followed by 7 d of PPI, amoxicillin, clarithromycin and metronidazole) or quadruple therapy with levofloxacin and bismuth – 14 d (PPI regime plus amoxicillin, bismuth and levofloxacin)[13-16]. Quadruple sequential therapy (14 d), hybrid therapy and non-bismuth quadruple concomitant therapy (14 d) are expected to fail if the rate of dual clarithromycin and metronidazole resistant strains are > 5%, > 9%, and > 15%, respectively[7]. Our results showed that antimicrobial susceptibility-guided triple therapies for 10 days in a population with clarithromycin – HP resistance > 16% and dual HP-resistance (clarithromycin, metronidazole or levofloxacin) > 12% was more effective than quadruple therapies for first-line (BQT or non-BQT) for first-line treatment.

In this study eradication rate of OAR for 10 d in naïve patients with triple HP-resistance (clarithromycin, metronidazole and levofloxacin) was 83% (5 of 6) *vs* 33% (2 of 6) in patients after two or three previous HP treatment failures. Several studies have confirmed that most of rifabutin-resistant isolates of HP were obtained from patients after treatment failures, suggesting that previous unsuccessful attempts of eradication seem to be an important risk factor for the development of resistance to rifabutin and/or multiple resistance[17,18]. Rifabutin rescue regimen is effective after multiple previous HP eradication failures[19,20]. A recent study, involving nine Spanish hospitals and 100 consecutive patients, supports that the use of rifabutin-based rescue therapy in patients with three HP eradication failures (OAC, BQT, and OAL, in all cases for 10 d) may be effective in approximately 50% of the cases[21].

Different virulence factors play an important role in the pathogenesis of HP and treatment resistance. For instance, a significant association has been found between dupA1 genotype and A214G clarithromycin resistance mutation by Hussein *et al*[22]. Further molecular studies are needed in order to clarify biomarkers that could causes of HP resistance.

Some of the limitations of this study were: first, the number of patients is too limited to draw definitive conclusions on the efficacy of these therapies. Second, rifabutin resistance evaluation was not assessed in patients treated with rifabutin-based triple therapy either before or after administration.

Dual or triple HP-resistance to various families of antimicrobials may be addressed by the adequate use of antibiotics, in a cost-effective manner and shortening the regimens as much as possible.

In summary, triple therapies including PPI and two antibiotics for 10 days, based in the knowledge of pretreatment antimicrobial susceptibility showed good eradication rates of HP infection in our region with and increased prevalence of dual or triple drugs HP-resistance (clarithromycin, metronidazole and/or levofloxacin).

**COMMENTS**

***Background***

Frequency of dual or triple antimicrobial resistance has been rising during the last decade and *Helicobacter pylori* (*H. pylori*) infections are an important challenge for physicians. To tailor recommendations for optimal treatments, efficacy evaluations must be performed in different geographical areas.

***Research frontiers***

*H. pylori* eradication therapy success is compromised mainly due to antibiotic resistance and numerous researchers are trying to overcome multiresistance. Resistance prevalence varies by country and within same region, by periods of time. The aim of this study was to evaluate the efficacy of antimicrobial susceptibility-guided therapy before first-line treatment for infection in patients with dual or triple antibiotic resistance.

***Innovations and breakthroughs***

In this study we demonstrated that in patients with dual clarithromycin, levofloxacin or metronidazole resistance, antimicrobial susceptibility-guided therapy including a combination of PPI and two antibiotics for 10 d leads to an eradication rate of 95.5%. Compared to different strategies previously purposed, our results shows that antimicrobial susceptibility-guided triple therapies for 10 days in a population with clarithromycin – HP resistance > 16% and dual HP-resistance (clarithromycin, metronidazole or levofloxacin) > 12% was more effective than quadruple therapies for first-line treatment of infections.

***Applications***

Dual or triple *H. pylori* resistance to various families of antimicrobials may be addressed by the adequate use of antibiotics in a cost-effective manner that allows shorter regimens.

***Terminology***

Common therapies for *H. pylori* treatment. Triple therapies: OAL (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and levofloxacin 500 mg b.i.d.) 43 cases, OAM (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and metronidazole 500 mg b.i.d.) 12 cases and OAC (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and clarithromicin 500 mg b.i.d.) 13 cases based on the antimicrobial susceptibility testing. Twelve patients showed triple HP-resistance and received for 10 d triple therapy with OAR (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and rifabutin 150 mg b.i.d.).

***Peer-review***

In the present paper, Cosme *et al* evaluated the impact of antimicrobial resistance in H. pylori in the first line eradication therapy. Starting from a sample size of 1034 patients undergoing culture, they selected cases with double or triple resistance and assigned a tailored triple therapy (omeprazole + amoxicillin + clarithromycin or metronidazole or levofloxacin or rifabutin). Therefore, they demonstrated a success rate > 90% in all regimens, excluding when rifabutin was adopted (58.3%) in triple resistant strains.

**REFERENCES**

1 **Thung I**, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. *Aliment Pharmacol Ther* 2016; **43**: 514-533 [PMID: 26694080 DOI: 10.1111/apt.13497]

2 **Fernandez-Reyes M,** Montes M, Lizasoain J, Piñeiro L, Bujanda L, Perez-Trallero E. Increased trend in Helicobacter pylori antimicrobial resistance during a 13 year period (2000-2012, Gipuzkoa, Basque Country, Spain). *Helicobacer* 2013; **18**: 103

3 **Martos M**, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendarte U, Fernández-Reyes M, Cosme A. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. *Eur J Gastroenterol Hepatol* 2014; **26**: 1380-1384 [PMID: 25229983 DOI: 10.1097/meg.0000000000000197]

4 **Perez-Trallero E**, Montes M, Larrañaga M, Arenas JI. How long for the routine Helicobacter pylori antimicrobial susceptibility testing? The usefulness of the string test to obtain Helicobacter for culture. *Am J Gastroenterol* 1999; **94**: 3075-3076 [PMID: 10520882 DOI: 10.1111/j.1572-0241.1999.3075\_e.x]

5 **Cosme A**, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, Piñeiro L, Recasens MT, Ibarra B, Sarasqueta C, Bujanda L. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. *Clin Microbiol Infect* 2013; **19**: 379-383 [PMID: 22512623 DOI: 10.1111/j.1469-0691.2012.03844.x]

6 **Malfertheiner P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]

7 **Georgopoulos SD**, Xirouchakis E, Mentis A. Is there a nonbismuth quadruple therapy that can reliably overcome bacterial resistance? *Gastroenterology* 2013; **145**: 1496-1497 [PMID: 24409502 DOI: 10.1053/j.gastro.2013.07.054]

8 [**Gisbert JP**](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gisbert%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=27342080)**,**[Molina-Infante J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Molina-Infante%20J%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Amador J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Amador%20J%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Bermejo F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bermejo%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Bujanda L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bujanda%20L%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Calvet X](https://www.ncbi.nlm.nih.gov/pubmed/?term=Calvet%20X%5BAuthor%5D&cauthor=true&cauthor_uid=27342080)6, [Castro-Fernández M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Castro-Fern%C3%A1ndez%20M%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Cuadrado-Lavín A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cuadrado-Lav%C3%ADn%20A%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Elizalde JI](https://www.ncbi.nlm.nih.gov/pubmed/?term=Elizalde%20JI%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Gene E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gene%20E%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Gomollón F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gomoll%C3%B3n%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Lanas Á](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lanas%20%C3%81%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Martín de Argila C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mart%C3%ADn%20de%20Argila%20C%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Mearin F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mearin%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Montoro M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Montoro%20M%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Pérez-Aisa Á](https://www.ncbi.nlm.nih.gov/pubmed/?term=P%C3%A9rez-Aisa%20%C3%81%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [Pérez-Trallero E](https://www.ncbi.nlm.nih.gov/pubmed/?term=P%C3%A9rez-Trallero%20E%5BAuthor%5D&cauthor=true&cauthor_uid=27342080), [McNicholl AG](https://www.ncbi.nlm.nih.gov/pubmed/?term=McNicholl%20AG%5BAuthor%5D&cauthor=true&cauthor_uid=27342080). IV Spanish Consensus Conference on Helicobacter pylori infection treatment. [*Gastroenterol Hepatol*](https://www.ncbi.nlm.nih.gov/pubmed/27342080) *2016*; **39**: 697-721 [PMID: 27342080 DOI: 10.1016/j.gastrohep]

9 **Laine L**, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. *Am J Gastroenterol* 2003; **98**: 562-567 [PMID: 12650788 DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x]

10 **Fischbach L**, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. *Aliment Pharmacol Ther* 2007; **26**: 343-357 [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x]

11 **Graham DY**, Lee SY. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. *Gastroenterol Clin North Am* 2015; **44**: 537-563 [PMID: 26314667 DOI: 10.1016/j.gtc.2015.05.003]

12 **Mégraud F**. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. *Therap Adv Gastroenterol* 2012; **5**: 103-109 [PMID: 22423259 DOI: 10.1177/1756283X11432492]

13 **Molina-Infante J**, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. *Gastroenterology* 2013; **145**: 121-128.e1 [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050]

14 **Molina-Infante J**, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. *World J Gastroenterol* 2014; **20**: 10338-10347 [PMID: 25132750 DOI: 10.3748/wjg.v20.i30.10338]

15 **Mc Nicholl AG**, Molina-Infantae J, Bermejo F, Yarb H, Ferrer-Barcelo L, Modolell I, Anton R, Alcedo J, Angeles Perez-Aisa M, Barenys M, Barrio J, Huerta A, Ortuno J, Fernandez-Bermejo M, Rodrigo L, Fernandez-Moreno N, Tomas A, Pozzati L, Herranz M, Almela P, Canelles P, Belén Vega A, Cosme A, Andreu V, Ferrer-Barcelo L, Huguet-Malaves JM, Algaba A, Marin AC, Gisbert P. Non bismuth quadruple “concomitant”therapies in the eradication of Helicobacter pylori. Standard vs optimized (14 days, high-dose PPI) regimes in clinical practice. *United Eur Gastroenterol J* 2015; **3**: A65

16 **Gisbert JP**, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. *Gastroenterol Hepatol* 2016; **39**: 697-721 [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003]

17 **Heep M**, Lehn N, Brandstätter B, Rieger U, Senzenberger S, Wehrl W. Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori. *Eur J Clin Microbiol Infect Dis* 2002; **21**: 143-145 [PMID: 11939398 DOI: 10.1007/s10096-001-0672-2]

18 **Glocker E**, Bogdan C, Kist M. Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany. *J Antimicrob Chemother* 2007; **59**: 874-879 [PMID: 17350989 DOI: 10.1093/jac/dkm039]

19 **Van der Poorten D**, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. *Aliment Pharmacol Ther* 2007; **26**: 1537-1542 [PMID: 17903237 DOI: 10.1111/j.1365-2036.2007.03531.x]

20 **Gisbert JP**, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. *Aliment Pharmacol Ther* 2012; **35**: 209-221 [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x]

21 **Gisbert JP**, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. *Aliment Pharmacol Ther* 2012; **35**: 941-947 [PMID: 22372560 DOI: 10.1111/j.1365-2036.2012.05053.x]

22 **Hussein NR**, Tunjel I, Majed HS, Yousif ST, Aswad SI, Assafi MS. Duodenal ulcer promoting gene 1 (dupA1) is associated with A2147G clarithromycin-resistance mutation but not interleukin-8 secretion from gastric mucosa in Iraqi patients. *New Microbes New Infect* 2015; **6**: 5-10 [PMID: 26042186 DOI: 10.1016/j.nmni.2015.02.005]

**P-Reviewer:** Emara MH, Hussein NR, Ierardi E, Yamaoka Y **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Spain

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B, B, B

Grade C (Good): 0


Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Demographic, clinical characteristics, eradication rates per intention-to-treat, compliance and adverse events of patients in each therapeutics group**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Dual HP - Resistance** | | | **Triple *H. pylori*- resistance** |
|  | **C+M** | **C+L** | **M+L** | **C+M+L** |
|  | **OAL-10** | **OAM-10** | **OAC-10** | **OAR-10** |
|  | **(43)** | **(12)** | **(13)** | **(12)** |
| Gender (females) | 70% | 67% | 69% | 67% |
| Age (yr)  Mean  Median (range) | 51.6  51 (18-76) | 52.8  52 (24-76) | 50  50 (31-75) | 53.3  53 (42-77) |
| Indication  Dyspepsia  Ulcer | 95%  5% | 83%  17% | 84%  16% | 75%  25% |
| ITT eradication | 42/43 (97.6%) | 11/12 (91.6%) | 12/13 (92.3%) | 7/12 (58.3%) |
| Compliance | 93% | 93% | 93% | 94% |
| Adverse events | 22% | 25% | 23% | 17% |

O: Omeprazole; A: Amoxicillin; L: Levofloxacin; M: Metronidazole; C: Clarithromycin; R: Rifabutin; *H. pylori*: *Helicobacter pylori*; ITT: Intention-to-treat.

 **Figure 1 Relation of simultaneous antibiotic resistance of *Helicobacter pylori* to various antibiotics in Gipuzkoa 2013/2014 (*n* = 1034).**



**Figure 2 Flow diagram of screening and follow-up of study subjects.** Susceptibility testing for HP resistance was performed in 1034 consecutive infected patients. A total of 157 patients showed dual (127, 12.3%) or triple (30, 2.9%) antibiotic resistance. Patients from Donosti area were selected for follow up (68 with dual and 12 with triple resistance). 43 patients resistant to clarithromycin and metronidazole but sensitive to levofloxacin were treated with levofloxacin-based triple therapy: omeprazole 20 mg, amoxicillin 1 g, and levofloxacin 500 mg (OAL); 12 patients resistant to both clarithromycin and levofloxacin were treated with metronidazole-based triple therapy: omeprazole 20 mg, amoxicillin 1 g, and metronidazole 500 mg (OAM); 13 resistant patietns to metronidazole and levofloxacin were treated with clarithromycin-based triple therapy: omeprazole 20 mg amoxicillin 1 g, and clarithromycin 500 mg (OAC), if the HP-strains werein all cases twice a day for 10 d. 12 patients with triple HP-resistance to clarithromycin, metronidazole and levofloxacin received rifabutin-based triple therapy: omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and rifabutin 150 mg b.i.d. (OAR) for 10 d.